CoChat

Drug testing and flow cytometry analysis on a large number of uniform sized tumor spheroids using a microfluidic device

Open access

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Abstract

Three-dimensional (3D) tumor spheroid possesses great potential as an in vitro model to improve predictive capacity for pre-clinical drug testing. In this paper, we combine advantages of flow cytometry and microfluidics to perform drug testing and analysis on a large number (5000) of uniform sized tumor spheroids. The spheroids are formed, cultured and treated with drugs inside a microfluidic device. The spheroids can then be harvested from the device without tedious operation. Due to the ample cell numbers, the spheroids can be dissociated into single cells for flow cytometry analysis. Flow cytometry provides statistical information in single cell resolution that makes it feasible to better investigate drug functions on the cells in more in vivo-like 3D formation. In the experiments, human hepatocellular carcinoma cells (HepG2) are exploited to form tumor spheroids within the microfluidic device and three anti-cancer drugs: Cisplatin, Resveratrol and Tirapazamine (TPZ) and their combinations are tested on the tumor spheroids with two different sizes. The experimental results suggest the cell culture format (2D monolayer vs. 3D spheroid) and spheroid size play critical roles in drug responses and also demonstrate the advantages of bridging the two techniques in pharmaceutical drug screening applications.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep21061

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 (A) Two-layered microfluidic devices for formation, culture, and drug testing of 5000 uniform-sized tumor spheroids with different culture chamber geometries (200 × 200 μm2 and 300 × 300 μm2) to prepare different sized spheroids. (B) Microscopic cross-sectional views of the devices with culture chamber geometries of 200 × 200 μm2 and 300 × 300 μm2 (width × length), and the height is 250 μm. Scale bar is 500 μm.
Figure 1 (A) Two-layered microfluidic devices for formation, culture, and drug testing of 5000 uniform-sized tumor spheroids with different culture chamber geometries (200 × 200 μm2 and 300 × 300 μm2) to prepare different sized spheroids. (B) Microscopic cross-sectional views of the devices with culture chamber geometries of 200 × 200 μm2 and 300 × 300 μm2 (width × length), and the height is 250 μm. Scale bar is 500 μm.CC BY · PubMed Central
Figure 2 (A) Cell seeding procedure: cell suspension is introduced into the device using a 200 μl pipette with a flow rate greater than 100 μl/min to achieve uniform distribution of the cells in the top layer microfluidic channel. The pipette tip is inserted into the blunt needle to assure the fast flow rate inside the device. (B) Culture medium exchange procedure: 1 ml of fresh medium (with drug when conducting drug testing) is added from the inlet. The gravity driven flow with a relative flow rate is exploited to replace the aged medium inside the device with minimal disturbance on the spheroids.
Figure 2 (A) Cell seeding procedure: cell suspension is introduced into the device using a 200 μl pipette with a flow rate greater than 100 μl/min to achieve uniform distribution of the cells in the top layer microfluidic channel. The pipette tip is inserted into the blunt needle to assure the fast flow rate inside the device. (B) Culture medium exchange procedure: 1 ml of fresh medium (with drug when conducting drug testing) is added from the inlet. The gravity driven flow with a relative flow rate is exploited to replace the aged medium inside the device with minimal disturbance on the spheroids.CC BY · PubMed Central
Figure 3 Size distribution analysis of the HepG2 tumor spheroids located in up-, middle- and down-stream of the microfluidic device and different devices with cell culture chamber dimensions (width × length) of (A) 200 × 200 μm2 and (B) 300 × 300 μm2, and the height is 250 μm. Data are expressed as the mean ± standard deviation (16 and 9 spheroids are analyzed in each location within a device with 200 × 200 μm2 and 300 × 300 μm2 cell culture chambers, respectively).
Figure 3 Size distribution analysis of the HepG2 tumor spheroids located in up-, middle- and down-stream of the microfluidic device and different devices with cell culture chamber dimensions (width × length) of (A) 200 × 200 μm2 and (B) 300 × 300 μm2, and the height is 250 μm. Data are expressed as the mean ± standard deviation (16 and 9 spheroids are analyzed in each location within a device with 200 × 200 μm2 and 300 × 300 μm2 cell culture chambers, respectively).CC BY · PubMed Central
Figure 4 Left: Flow-cytometry analysis of dissociated HepG2 tumor spheroids with forward-scattering light (FSC), side-scattering light (SSC), and gated areas. Right: Viability assay using Calcein-AM and 7-AAD (right panel) on dissociated HepG2 tumor spheroids after 3-day culture in the microfluidic devices with cell culture chamber dimensions (width × length) of (A) 200 × 200 μm2 and (B) 300 × 300 μm2, and the height is 250 μm.
Figure 4 Left: Flow-cytometry analysis of dissociated HepG2 tumor spheroids with forward-scattering light (FSC), side-scattering light (SSC), and gated areas. Right: Viability assay using Calcein-AM and 7-AAD (right panel) on dissociated HepG2 tumor spheroids after 3-day culture in the microfluidic devices with cell culture chamber dimensions (width × length) of (A) 200 × 200 μm2 and (B) 300 × 300 μm2, and the height is 250 μm.CC BY · PubMed Central
Figure 5 Bright field microscopic images of the HepG2 tumor spheroids cultured in the microfluidic devices with cell culture chamber dimensions (width × length) of (A) 200 × 200 μm2 and (B) 300 × 300 μm2, and the height is 250 μm for total 3 days and treated with drugs for 48 hours. (C) Quantitative characterization of the diameters of the HepG2 tumor spheroids before and after the drug treatments by imaging analysis on the bright field microscopic images.
Figure 5 Bright field microscopic images of the HepG2 tumor spheroids cultured in the microfluidic devices with cell culture chamber dimensions (width × length) of (A) 200 × 200 μm2 and (B) 300 × 300 μm2, and the height is 250 μm for total 3 days and treated with drugs for 48 hours. (C) Quantitative characterization of the diameters of the HepG2 tumor spheroids before and after the drug treatments by imaging analysis on the bright field microscopic images.CC BY · PubMed Central
Figure 6 Density plots of flow cytometry analysis on APC-Annexin V and 7-AAD stained HepG2 cells (apoptosis and necrosis assay) cultured in 2D Petri-dish and dissociated from different sized tumor spheroids after 48-hour drug treatments.
Figure 6 Density plots of flow cytometry analysis on APC-Annexin V and 7-AAD stained HepG2 cells (apoptosis and necrosis assay) cultured in 2D Petri-dish and dissociated from different sized tumor spheroids after 48-hour drug treatments.CC BY · PubMed Central
Figure 7 Density plots of flow cytometry analysis on APC-Annexin V and 7-AAD stained HepG2 cells (apoptosis and necrosis assay) cultured in 2D Petri-dish and dissociated from tumor spheroids formed in 300 × 300 μm2 (width × length) cell culture chambers after 48-hour treatments of drug combinations.
Figure 7 Density plots of flow cytometry analysis on APC-Annexin V and 7-AAD stained HepG2 cells (apoptosis and necrosis assay) cultured in 2D Petri-dish and dissociated from tumor spheroids formed in 300 × 300 μm2 (width × length) cell culture chambers after 48-hour treatments of drug combinations.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

5 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

Items 201–215 of 215

Metadata

Authors
Patra, B., Peng, C.-C., Liao, W.-H., Lee, C.-H., & Tung, Y.-C.
Affiliations
  • Research Center for Applied Science, Academia Sinica (TW)
  • National Taiwan University (TW)
Corresponding author
Tung, Yi-Chung
Venue
Scientific Reports
Published
2016-02-15
Volume
6
Issue
1
Pages
21061-21061
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2418686488
Cited by
215
References
36
Citations by year
2026: 6 · 2025: 15 · 2024: 20 · 2023: 20 · 2022: 23 · 2021: 29 · 2020: 18 · 2019: 23 · 2018: 24 · 2017: 27 · 2016: 10
FWCI
13.50
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Academia Sinica
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
  • Physical Sciences › Engineering › Biomedical Engineering › Microfluidic and Capillary Electrophoresis Applications
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords
tumor spheroids, microfluidics, drug screening, flow cytometry, 3D cell culture, hepatocellular carcinoma, HepG2 cells, cisplatin, resveratrol, tirapazamine, combination therapy, spheroid size, 2D vs 3D cell culture, single-cell analysis
MeSH terms
Drug Screening Assays, Antitumor, Flow Cytometry, Humans, Spheroids, Cellular, Cell Culture Techniques, Microfluidic Analytical Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.